Noa G Holtzman

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 11

Top Venues

Blood advances

British journal of haematology

Cancer chemotherapy and pharmacology

Blood

This page only lists publications with an associated author ORCID identifier.

Publications

Noa G Holtzman, Lauren M Curtis, Rachel B Salit, Brian C Shaffer, Filip Pirsl, Alen Ostojic, Seth M Steinberg, Eduard Schulz, Jennifer S Wilder, Thomas E Hughes, Jeremy Rose, Sarfraz Memon, Robert Korngold, Juan C Gea-Banacloche, Daniel H Fowler, Frances T Hakim, Ronald E Gress, Michael R Bishop, Steven Z Pavletic
High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention. Blood advances 8 (16) (2024)
Noa G Holtzman, Lauren M Curtis, Rachel B Salit, Brian C Shaffer, Filip Pirsl, Alen Ostojic, Seth M Steinberg, Eduard Schulz, Jennifer S Wilder, Thomas E Hughes, Jeremy Rose, Sarfraz Memon, Robert Korngold, Juan C Gea-Banacloche, Daniel H Fowler, Frances T Hakim, Ronald E Gress, Michael R Bishop, Steven Z Pavletic
High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention. Blood advances 8 (16) (2024)
Noa G Holtzman, Lauren M Curtis, Rachel B Salit, Brian C Shaffer, Filip Pirsl, Alen Ostojic, Seth M Steinberg, Eduard Schulz, Jennifer S Wilder, Thomas E Hughes, Jeremy Rose, Sarfraz Memon, Robert Korngold, Juan C Gea-Banacloche, Daniel H Fowler, Frances T Hakim, Ronald E Gress, Michael R Bishop, Steven Z Pavletic
High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention. Blood advances 8 (16) (2024)
Noa G Holtzman, Lauren M Curtis, Rachel B Salit, Brian C Shaffer, Filip Pirsl, Alen Ostojic, Seth M Steinberg, Eduard Schulz, Jennifer S Wilder, Thomas E Hughes, Jeremy Rose, Sarfraz Memon, Robert Korngold, Juan Gea-Banacloche, Daniel H Fowler, Frances T Hakim, Ronald E Gress, Michael R Bishop, Steven Z Pavletic
High-dose Alemtuzumab-Cyclosporine vs Tacrolimus-Methotrexate-Sirolimus for Chronic Graft-versus-Host Disease Prevention. Blood advances (2024)
Noa G Holtzman, Steven Z Pavletic
W"H-Y" antigen/HLA complexes in chronic GVHD. Blood 142 (11) (2023)
Yifan Pang, Ananth V Charya, Michael B Keller, Arlene Sirajuddin, Yi-Ping Fu, Noa G Holtzman, Steven Z Pavletic, Sean Agbor-Enoh
A starting point for the phenotypic classification of pulmonary chronic graft-versus-host disease. Blood advances 6 (17) (2022)
Yifan Pang, Ananth V Charya, Michael B Keller, Arlene Sirajuddin, Yi-Ping Fu, Noa G Holtzman, Steven Z Pavletic, Sean Agbor-Enoh
The ISHLT chronic lung allograft dysfunction consensus criteria are applicable to pulmonary chronic graft-versus-host disease. Blood advances 6 (14) (2022)
Sarah M Kashanian, Noa G Holtzman, Ciera L Patzke, Jonathan Cornu, Alison P Duffy, Madhurima Koka, Sandrine Niyongere, Vu H Duong, Maria R Baer, Jummai Apata, Farin Kamangar, Ashkan Emadi
Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens. Cancer chemotherapy and pharmacology 87 (6) (2021)
Noa G Holtzman, Steven Z Pavletic
The clinical landscape of chronic graft-versus-host disease management in 2021. British journal of haematology (2021)
Forat Lutfi, Noa G Holtzman, Ankit J Kansagra, Moaath Mustafa Ali, Ali Bukhari, Jingsheng Yan, Santanu Samanta, David Gottlieb, Dong W Kim, Lisa R Matsumoto, Natalie Gahres, Kathleen Ruehle, Seung T Lee, Jennie Y Law, Mehmet H Kocoglu, Djordje Atanackovic, Jean A Yared, Nancy M Hardy, Jason Molitoris, Pranshu Mohindra, Aaron P Rapoport, Saurabh Dahiya
The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma. British journal of haematology 195 (3) (2021)
Noa G Holtzman, Firas El Chaer, Maria R Baer, Omer Ali, Ameet Patel, Vu H Duong, Edward A Sausville, Zeba N Singh, Rima Koka, Ying S Zou, Arash Etemadi, Ashkan Emadi
Peripheral blood blast rate of clearance is an independent predictor of clinical response and outcomes in acute myeloid leukaemia. British journal of haematology 188 (6) (2019)

Noa G Holtzman.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Noa G Holtzman